"The
Report PharmaPoint: Peripheral Artery Disease - Global Drug Forecast
and Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
In the 2014 base year, the
global PAD market was worth approximately $543.4m, including both
branded and generic drugs. By 2024, GlobalData expects that the
global PAD market will experience significant expansion, with a
Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating
to around $816.3m. The dramatic increase in the value of the overall
global PAD therapeutics market will be partly attributable to the
launch of several PAD drugs currently in late-stage pipeline
development, which GlobalData believes have extraordinary potential.
These include the novel antithrombotic pharmacological agents, Merck
& Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor),
and Bayer and Janssens (a subsidiary of Johnson & Johnson)
Xarelto (rivaroxaban), which have the capacity to reform the
antiplatelet and anticoagulatory PAD treatment landscape.
GlobalData believes that the
size of the market for pharmacological agents designed to alleviate
PAD symptoms, including cilostazol, naftidrofuryl, and
pentoxifylline, will diminish throughout the forecast period.
GlobalData accredits this diminishing to three factors: first, the
advent of advanced revascularization procedures, as characterized by
gradual, incremental improvements in success rates over time; second,
the fact that current drug treatments, such as the ones mentioned
above, display lackluster efficacy, perturbing safety attributes, and
inconvenient dosing regimens; and third, the lack of novel, superior,
premium-priced, drug therapies in the late stages of the PAD pipeline
that could encroach on the patient shares of existing, rival
pharmacological treatments.
The overall level of unmet need
in the PAD market is high, resulting in a generous amount of room for
new entrants to capitalize on. With respect to the first three
traditional pillars of PAD treatment - antithrombotic pharmacological
agents, lipid-lowering medical therapies, and antihypertensive drugs
- the level of unmet need will fall once the current crop of
late-phase PAD therapies portrayed in this report arrives onto the
market. With respect to drugs that allay the symptoms of PAD, the
level of unmet need here is astronomical. Present medical treatments
are limited, archaic, and some have restricted availability.
View Report At
:http://www.marketresearchreports.biz/analysis/511689
Highlights
Key Questions Answered
-
From a clinical standpoint, there is a demand for novel medical
therapies that target and relieve the symptoms of PAD in IC and CLI
patients. KOLs interviewed by GlobalData expressed a desire for
second-generation drug treatments that display superior efficacy and
favorable safety profiles compared to existing pharmacological.
Environmental unmet needs for this particular indication include
physician education, patient awareness, greater screening, and
improved guidelines. What other unmet needs exist in this market?
Will the drugs under development fulfil the unmet needs of the PAD
market?
-
The current late-stage PAD pipeline encompasses AstraZenecas
Brillinta, Bayer/Janssens Xarelto and Mercks Zontivity. Will the
late-stage drugs make a significant impact on the PAD market? Which
of these drugs will have the highest peak sales at the highest CAGR,
and why?
Key Findings
-
The major drivers of this expansion in the PAD market will be the
advent of novel antithrombotic agents, such as Brilinta and Xarelto,
onto the PAD stage, and the increasing prevalence of PAD across all
of the 8MM.
-
The major global barrier to growth in the PAD market will be the
losses of patent protection and market exclusivity on marketed and
key pipeline drugs during the forecast period, such as AstraZenecas
Crestor (rosuvastatin), Sanofis Plavix (clopidogrel), Brilinta, and
Xarelto.
-
The overall level of unmet need in the PAD market is high, resulting
in a generous amount of room for new entrants to capitalize on.
GlobalData forecasts that once Brilinta and Xarelto, pipeline
pharmacological agents currently in late-stage clinical trials for
PAD, navigate their way through the regulatory landscape and secure
approval for the PAD indication, they will address some of the unmet
needs in this area.
Download
Sample copy of this Report at:
Scope
-
Overview of peripheral artery disease (PAD), including epidemiology,
etiology, pathophysiology, symptoms, diagnosis, and treatment
guidelines.
-
Annualized PAD therapeutics market revenue, annual cost of therapy
and treatment usage pattern data from 2014 and forecast for ten years
to 2024.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the PAD therapeutics market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
late-stage pipeline drugs.
-
Analysis of the current and future market competition in the global
PAD therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global PAD therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies,
market
segments, and companies likely to impact the global PAD therapeutics
market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global PAD therapeutics market from
2014-2024.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table
Of Content
1
Table of Contents 12
1.1
List of Tables 18
1.2
List of Figures 22
2
Introduction 25
2.1
Catalyst 25
2.2
Related Reports 26
2.3
Upcoming Related Reports 26
3
Disease Overview 27
3.1
Etiology and Pathophysiology 28
3.1.1
Etiology 28
3.1.2
Pathophysiology 30
3.2
Classification and Staging Systems 31
3.3
Symptoms and Clinical Presentation 33
3.4
Prognosis 37
3.5
Quality of Life 41
4
Epidemiology 43
4.1
Disease Background 43
4.2
Risk Factors and Comorbidities 44
4.3
Global Trends 46
4.4
Forecast Methodology 47
4.4.1
Sources Used 48
4.4.2
Sources Not Used 61
4.4.3
Forecast Assumptions and Methods 61
4.5
Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024)
67
4.5.1
Total Prevalent Cases of PAD 67
4.5.2
Age-Specific Total Prevalent Cases of PAD 68
4.5.3
Sex-Specific Total Prevalent Cases of PAD 70
4.5.4
Age-Adjusted Total Prevalence of PAD 72
4.5.5
Total Prevalent Asymptomatic and Symptomatic Cases of PAD 73
4.5.6
Total Prevalent Cases of PAD with Intermittent Claudication and PAD
with Critical Limb Ischemia 75
4.5.7
Proportion of Total PAD Cases that Present as Asymptomatic, PAD with
Intermittent Claudication, and PAD with Critical Limb Ischemia 77
4.5.8
Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes
78
4.6
Epidemiological Forecast of Diagnosed Prevalent Cases of PAD
(2014-2024) 80
4.6.1
Diagnosed Prevalent Cases of PAD 80
4.6.2
Age-Specific Diagnosed Prevalent Cases of PAD 82
4.6.3
Sex-Specific Diagnosed Prevalent Cases of PAD 84
4.6.4
Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD 86
4.6.5
Diagnosed Prevalent Cases of PAD with Intermittent Claudication and
PAD with Critical Limb Ischemia 88
4.6.6
Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD
with Intermittent Claudication, and PAD with Critical Limb Ischemia
90
4.6.7
Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with
Diabetes 91
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment